Monika Janda, Kristy P Robledo, Val Gebski, Jane E Armes, Michelle Alizart, Margaret Cummings, Chen Chen, Yee Leung, Peter Sykes, Orla McNally, Martin K Oehler, Graeme Walker, Andrea Garrett, Amy Tang, Russell Land, James L Nicklin, Naven Chetty, Lewis C Perrin, Greet Hoet, Katherine Sowden, Lois Eva, Amanda Tristram, Andreas Obermair
PURPOSE: Intrauterine levonorgestrel (LNG-IUD) is used to treat patients with endometrial adenocarcinoma (EAC) and endometrial hyperplasia with atypia (EHA) but limited evidence is available on its effectiveness. The study determined the extent to which LNG-IUD with or without metformin (M) or weight loss (WL) achieves a pathological complete response (pCR) in patients with EAC or EHA. PATIENTS AND METHODS: This phase II randomized controlled clinical trial enrolled patients with histologically confirmed, clinically stage 1 FIGO grade 1 EAC or EHA; a body mass index > 30 kg/m2; a depth of myometrial invasion of less than 50% on MRI; a serum CA125 ≤ 30 U/mL...
April 2021: Gynecologic Oncology